Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes

Anaplastic lymphoma kinase (ALK) is a validated molecular target in several ALK-rearranged malignancies, particularly in non-small-cell lung cancer (NSCLC), which has generated considerable interest and effort in developing ALK tyrosine kinase inhibitors (TKI). Crizotinib was the first ALK inhibitor...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancers (Basel)
Asıl Yazarlar: Sharma, Geeta Geeta, Mota, Ines, Mologni, Luca, Patrucco, Enrico, Gambacorti-Passerini, Carlo, Chiarle, Roberto
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: MDPI 2018
Konular:
Review
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5876637/
https://ncbi.nlm.nih.gov/pubmed/29495603
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers10030062
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller